ENSYSCE BIOSCIENCES INC (ENSC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.47+0.30%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Ensysce Biosciences aims to resolve Nasdaq listing issues to avoid delisting. The company targets reducing operating losses near negative $3.56 million and improving revenue above $0.96 million next quarter. Recent EPS estimates improved from negative $0.69 to negative $0.49 for 2026-Q3. These steps could stabilize the business and support a recovery.
The company faces ongoing Nasdaq non-compliance risking delisting. Operating losses remain large near negative $3.56 million and cash burn worsened to negative $3.5 million. Revenue is inconsistent, fluctuating between $0.49 million and $1.88 million, showing no steady growth. The stock has fallen over 50% from highs, reflecting these risks.
The market is selling off ENSC shares sharply, reflecting risks from Nasdaq delisting and persistent losses. There is no clear consensus revenue or price target, indicating uncertainty. Our view differs by focusing on the company’s ability to resolve listing issues and reduce losses as key to any recovery.
Breaks if: Nasdaq issues persist or worsen beyond 2026-Q3
Resolve Nasdaq listing non-compliance related to stockholders' equity to maintain listing status.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, but it is trying to advance its product pipeline and has recently completed an acquisition.
The market seems to have priced in a low level of fragility, with expectations that are somewhat justified. ENSC is viewed as cheap compared to its peers, but there is a notable expectations gap.
Management has made progress with the acquisition of Cy Biopharma and is advancing clinical trials for its opioid deterrent. However, the company continues to face high cash burn and ongoing operating losses, which could limit its financial stability in the near term.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as their results could significantly influence investor sentiment. Additionally, the company's ability to manage cash flow and execute on its strategic priorities will be crucial.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat strengthens the read on ENSC. However, revenue fell short of estimates, which challenges cash flow management and operating losses.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q1. The company received Nasdaq notice for non-compliance with the $2.5 million stockholders' equity requirement as of March 31, 2026. Financials show stockholders' equity was negative $669,012 at 2026-Q1, confirming the deficiency. This indicates a regulatory challenge that management must address to maintain listing.
“Received notice from Nasdaq for non-compliance with $2.5 million stockholders' equity requirement as of March 31, 2026.”
Breaks if: Operating losses worsen beyond negative $3.56 million next quarter
Breaks if: Revenue falls below $0.96 million next quarter
In the next 1 to 3 years, ENSC's performance will largely depend on external sector dynamics and internal execution on strategic initiatives. Not investment advice.